Logo

AstraZeneca Divests Rights of its Nexium and Vimovo Product to Grunenthal

Share this

AstraZeneca Divests Rights of its Nexium and Vimovo Product to Grunenthal

Shots:

  • AZ will receive an upfront $700M & $115M plus milestone payments up to $90M & $17M for Nexium (esomeprazole) and Vimovo (naproxen/esomeprazole) respectively. Grunenthal to get commercialization rights for Nexium in EU & WW rights for Vimovo (except in the US & Japan)
  • AZ will continue to manufacture and supply Nexium under the long-term supply agreement having its global commercialization rights except in EU
  • Nexium a proton pump inhibitor indicated for gastroesophageal reflux disease- ulcers- and Zollinger-Ellison syndrome & Vimovo is a FD combination drug of naproxen- for OA- RA & AS having net sales $121M in EU & $37M WW (except the US & Japan) respectively
  • In 2012 & 2013- Pfizer Consumer Health & Horizon Pharma gained rights for Nexium (over-the-counter) & Vimovo (in the US) from AZ respectively

Ref: AstraZeneca | Image: AstraZeneca


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions